- Home
- SENS vs NGEN Comparison
SENS vs NGEN Comparison
Compare SENS & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SENS | NGEN |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | Canada |
| Employees | N/A | 14 |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.5M | 337.4M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | SENS | NGEN |
|---|---|---|
| Price | $6.77 | $4.11 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $18.38 | N/A |
| AVG Volume (30 Days) | ★ 301.7K | 217.5K |
| Earning Date | 05-07-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,389,000.00 | N/A |
| Revenue This Year | $74.15 | N/A |
| Revenue Next Year | $58.60 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.85 | N/A |
| 52 Week Low | $0.41 | $3.51 |
| 52 Week High | $8.75 | $5.93 |
Technical Indicators
Market Signals| Indicator | SENS | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 51.82 | 49.99 |
| Support Level | $6.62 | $3.65 |
| Resistance Level | $6.87 | $4.52 |
| Average True Range (ATR) | 0.32 | 0.28 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 72.35 | 45.71 |
Price Performance
Historical ComparisonAbout SENS Senseonics Holdings Inc.
Senseonics Holdings Inc is a medical technology company. It is focused on the design, development, and commercialization of glucose monitoring system, which helps people to manage their diabetes community with differentiated, long-term implantable glucose management technology. Its products and services include a Continuous glucose monitoring system, Sensor, Smart transmitter, and Mobile app. The firm has a Glucose monitoring product segment. The majority of the revenue is generated outside of the United States.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.